Cloney Michael Brendan, Sonabend Adam M, Yun Jonathan, Yang Jingyan, Iwamoto Fabio, Singh Suprit, Bhagat Govind, Canoll Peter, Zanazzi George, Bruce Jeffrey N, Sisti Michael, Sheth Sameer, Connolly E Sander, McKhann Guy
Department of Neurological Surgery, College of Physicians and Surgeons, Columbia University Medical Center, 710 W 168th Street, Room 426, New York, NY, 10032, USA.
Department of Epidemiology, The Mailman School of Public Health, Columbia University, New York, NY, USA.
J Neurooncol. 2017 Mar;132(1):189-197. doi: 10.1007/s11060-016-2358-8. Epub 2017 Jan 23.
Surgical resection is not the standard of care for primary central nervous system lymphoma (PCNSL), as historical studies have demonstrated unfavorable complication rates and limited benefits. Some recent studies suggest that resection may provide a therapeutic benefit, yet the safety of these procedures has not been systematically investigated in the setting of modern neurosurgery. We examined the safety of surgical resection for PCNSL. We retrospectively analyzed all patients with PCNSL treated at Columbia University Medical Center between 2000 and 2015 to assess complications rates following biopsy or resection using the Glioma Outcomes Project system. We identified predictors of complications and selection for resection. Well-validated scales were used to quantify patients' baseline clinical characteristics, including functional status, comorbid disease burden, and cardiac risk. The overall complication rate was 17.2% after resection, and 28.2% after biopsy. Cardiac risk (p = 0.047, OR 1.72 [1.01, 2.95]), and comorbid diagnoses (p = 0.004, OR 3.05 [1.42, 6.57]) predicted complications on multivariable regression. Patients who underwent resection had better KPS scores (median 70 v. 80, p = 0.0068, ∆ 10 [0.0, 10.00]), and were less likely to have multiple (46.5% v. 27.6%, p = 0.030, OR 1.42 [1.05, 1.92]) or deep lesions (70.4% v. 39.7%, p = 0.001, OR 1.83 [1.26, 2.65]). Age (p = 0.048, OR 0.75 per 10-year increase [0.56, 1.00]) and deep lesions (p = 0.003, OR 0.29 [0.13, 0.65]) influenced selection for resection on multivariable regression. Surgical resection of PCNSL is safe for select patients, with complication rates comparable to rates for other intracranial neoplasms. Whether there is a clinical benefit to resection cannot be concluded.
手术切除并非原发性中枢神经系统淋巴瘤(PCNSL)的标准治疗方法,因为既往研究表明其并发症发生率高且益处有限。近期一些研究表明,切除可能具有治疗益处,但在现代神经外科手术中,这些手术的安全性尚未得到系统研究。我们研究了PCNSL手术切除的安全性。我们回顾性分析了2000年至2015年间在哥伦比亚大学医学中心接受治疗的所有PCNSL患者,使用胶质瘤结局项目系统评估活检或切除后的并发症发生率。我们确定了并发症的预测因素以及切除的选择标准。使用经过充分验证的量表来量化患者的基线临床特征,包括功能状态、合并疾病负担和心脏风险。切除后的总体并发症发生率为17.2%,活检后为28.2%。心脏风险(p = 0.047,比值比1.72 [1.01, 2.95])和合并诊断(p = 0.004,比值比3.05 [1.42, 6.57])在多变量回归中可预测并发症。接受切除的患者KPS评分更高(中位数70对80,p = 0.0068,差值10 [0.0, 10.00]),且发生多发病变(46.5%对27.6%,p = 0.030,比值比1.42 [1.05, 1.92])或深部病变(70.4%对39.7%,p = 0.001,比值比1.83 [1.26, 2.65])的可能性较小。年龄(p = 0.048,每增加10岁比值比0.75 [0.56, 1.00])和深部病变(p = 0.003,比值比0.29 [0.13, 0.65])在多变量回归中影响切除的选择。对于特定患者,PCNSL的手术切除是安全的,并发症发生率与其他颅内肿瘤相当。切除是否具有临床益处尚不能得出结论。